Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$754.14
Price-0.63%
-$4.77
1Y
Price
Market Cap
$77.889b
Large
Price/Earnings 3y Avg5y Avg
18.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+51.1%
EBITDA Margin+38.9%
Net Profit Margin+37.8%
Free Cash Flow Margin+51.1%
EBITDA Margin+38.9%
Net Profit Margin+37.8%
Free Cash Flow MarginRevenue
$14.248b
+0.3%
1y CAGR+5.5%
3y CAGR-2.0%
5y CAGREarnings
$4.578b
+3.8%
1y CAGR+2.2%
3y CAGR-9.9%
5y CAGREPS
$41.76
+8.9%
1y CAGR+3.4%
3y CAGR-9.2%
5y CAGRBook Value
$30.958b
$40.169b
Assets$9.212b
Liabilities$2.706b
DebtDebt to Assets
6.7%
0.5x
Debt to EBITDAFree Cash Flow
$4.154b
+13.4%
1y CAGR-1.3%
3y CAGR-9.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company